This is a prototype that includes a limited number of companies. To leave feedback or stay updated on our progress, fill out this form.

Company overview



Company type:

Recent funding

Round Amount raised ($M) Date closed Lead investors Other new investors Existing investors

* Includes fundings from Jan 2018 through March 2021

Pipeline summary

Product name Modality Target Indication Preclinical Phase 1 Phase 2 Phase 3 FDA submission Commercial

US patents

Assignees Assignors Title Identifiers Key dates Inventors

Clinical trials

NCT ID Title Summary Phase Condition Design Start date Primary completion date Completion date Enrollment Arms Primary outcome Secondary outcomes

Competition by target

Molecule name Therapeutic modality Target Action type Mechanism of action Brand names Companies Number of clinical trials Indications of clinical trials Stages of clinical trials

IPO comps

Company name Ticker Series A date Series A amount raised Series A post-money Series B date Series B amount raised Series B post-money Series C date Series C amount raised Series C post-money IPO date IPO amount raised IPO post-money Therapeutic areas Therapeutic modalities Stage

M&A comps

Company name Acquiror name Deal date Upfront value ($M) Total value ($M) Therapeutic areas Development stage

Comparable venture fundings

Company name Date Round Amount invested Therapeutic areas Stage Location Lead investors New non-lead investors Existing investors